tirzepatide for menopause symptoms New study links combination of hormone therapy and to greater weight loss after Postmenopausal women on the GLP-1

The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board

There could be issues with sterility, which is especially important to consider with injectable medications, like semaglutide

Insulin resistance and PCOS are closely connected, as people with PCOS often have the condition

How long does treatment last

Your provider will assess your individual circumstances and adjust accordingly

The most commonly reported neurological side effects of Wegovy are headache and dizziness, both classified as common in the Summary of Product Characteristics